Castleark Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Castleark Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-54,440	Closed	-$6.46M	–	358
2022 Q1	$6.46M	Buy	54,440 +9,990	+22%	+$1.25M	0.28%	88
2021 Q4	$6.13M	Buy	+44,450	New	+$5.65M	0.23%	109
2021 Q1	–	Sell	-67,716	Closed	-$5.8M	–	387
2020 Q4	$5.8M	Sell	67,716 -60,245	-47%	-$5.11M	0.22%	126
2020 Q3	$8.32M	Buy	127,961 +37,511	+41%	+$2.46M	0.33%	91
2020 Q2	$6.61M	Buy	+90,450	New	+$4.81M	0.29%	103
2019 Q3	–	Sell	-67,240	Closed	-$2.94M	–	418
2019 Q2	$2.94M	Buy	+67,240	New	+$3.79M	0.11%	189

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Castleark Management's BHVN Position: Q2 2022 in Review

Castleark Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 54,440 shares — an estimated $6.46M sold.

Castleark Management first reported a position in BHVN in Q2 2019 and held it in 6 quarters. The position peaked at $8.32M in Q3 2020. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Castleark Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Castleark Management sold 54,440 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $6.46M.
Castleark Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 6 quarters.
Castleark Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $8.32M in Q3 2020.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Castleark Management's 13F filing for Q2 2022, filed 16 Aug 2022.